| P50 | author | Angelo Paci | Q56956533 |
| | Sophie Broutin | Q56527799 |
| P2093 | author name string | J M Bidart | |
| | R Farinotti | |
| | C Jovelet | |
| | S Gil | |
| | A Deroussent | |
| P2860 | cites work | Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays | Q25939005 |
| | Multidrug resistance in cancer: role of ATP-dependent transporters | Q28208049 |
| | Vandetanib (Zactima, ZD6474) antagonizes ABCC1- and ABCG2-mediated multidrug resistance by inhibition of their transport function | Q28475378 |
| | Targeting multidrug resistance in cancer | Q29616803 |
| | Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump | Q33204719 |
| | Tissue distribution and metabolism of the tyrosine kinase inhibitor ZD6474 (Zactima) in tumor-bearing nude mice following oral dosing | Q33241437 |
| | Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer | Q33710562 |
| | Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy | Q33828409 |
| | Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1. | Q34135435 |
| | The Role of ABC Transporters in Clinical Practice | Q34268081 |
| | Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial | Q34271566 |
| | Role of tyrosine kinase inhibitors in cancer therapy | Q34432091 |
| | Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial | Q35576189 |
| | ZD6474--a novel inhibitor of VEGFR and EGFR tyrosine kinase activity | Q36146888 |
| | Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. | Q36536479 |
| | ZD6474 reverses multidrug resistance by directly inhibiting the function of P-glycoprotein | Q36611278 |
| | Mechanism of multidrug recognition by MDR1/ABCB1. | Q36869385 |
| | Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties | Q37447522 |
| | The emergence of drug transporter-mediated multidrug resistance to cancer chemotherapy | Q37902635 |
| | Inhibition of P-glycoprotein functionality by vandetanib may reverse cancer cell resistance to doxorubicin | Q39368066 |
| | Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences | Q39842857 |
| | Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance | Q40050525 |
| | Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer | Q40489484 |
| | Interaction of imatinib mesilate with human P-glycoprotein | Q40634392 |
| | Pharmacokinetics and tolerability of vandetanib in Chinese patients with solid, malignant tumors: an open-label, phase I, rising multiple-dose study | Q42601834 |
| | Pharmacokinetic resistance to imatinib mesylate: role of the ABC drug pumps ABCG2 (BCRP) and ABCB1 (MDR1) in the oral bioavailability of imatinib | Q45196167 |
| | Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice | Q46413821 |
| | Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors | Q46499714 |
| | Rapid and sensitive LC/MS/MS analysis of the novel tyrosine kinase inhibitor ZD6474 in mouse plasma and tissues | Q46527452 |
| | Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps | Q46560498 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacokinetics | Q323936 |
| P304 | page(s) | 149-157 | |
| P577 | publication date | 2013-02-28 | |
| P1433 | published in | European Journal of Drug Metabolism and Pharmacokinetics | Q15757261 |
| P1476 | title | Influence of the multidrug transporter P-glycoprotein on the intracellular pharmacokinetics of vandetanib | |
| P478 | volume | 38 | |